<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918736</url>
  </required_header>
  <id_info>
    <org_study_id>NSC96-2314-B-075B-006</org_study_id>
    <nct_id>NCT00918736</nct_id>
  </id_info>
  <brief_title>Efficacy of 3 Weekly Injections of Hyaluronate in Patients With Ankle Osteoarthritis</brief_title>
  <official_title>Hyaluronans in the Treatment of Ankle Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to investigate the efficacy and safety of three weekly
      intraarticular injections of Hyaluronate (HA) in patients with unilateral ankle
      Osteoarthritis (OA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Viscosupplementation with 3 to 5 weekly hyaluronate injections is a well-established
      treatment option in knee osteoarthritis. Previous studies reported that five weekly
      hyaluronate injections were safe and effective for the treatment of ankle osteoarthritis.
      However, the effect of three weekly injections has rarely been investigated. Besides, no
      study to date has assessed whether balance function would change after HA injections in
      patients with ankle OA. The purpose of this study was to evaluate the efficacy and safety of
      three weekly injections of sodium hyaluronate (Hyalgan) in patients with unilateral ankle
      osteoarthritis. Pain, physical function and balance will be assessed as parameters for the
      effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Ankle Osteoarthritis Scale (AOS) Score at 6 Months</measure>
    <time_frame>baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The American Orthopedic Foot and Ankle Society (AOFAS) Ankle/Hindfoot Score</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle Sagittal Range of Motion</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Four Clinical Balance Tests</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Level of Global Satisfaction Based on a 7-Point Categorical Scale</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic and Local Adverse Events Recording</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Acetaminophen Consumption</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>hyaluronate injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium hyaluronate</intervention_name>
    <description>3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.</description>
    <arm_group_label>hyaluronate injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  were 18 years of age or older, reported unilateral ankle pain for at least 6 months
             and had either reported no significant benefit from conservative treatment (rest,
             physical therapy, orthoses or pain medications etc.) or were unable to tolerate side
             effects of medications

          -  ankle radiographs taken within 6 months were equivalent to grade 2 or 3 according to
             the Kellgren-Lawrence grading system (grade 2, definite osteophytes and possible
             narrowing of joint space; grade 3, moderate multiple osteophytes, definite narrowing
             of joint space, some sclerosis and possible deformity of bone contour)22

          -  had a current total AOS score (described below) of &gt; 3 and &lt; 9 (possible range, 0-10)

          -  were normally active, not bedridden or confined to a wheelchair, and were able to walk
             30 meters without the aid of a walker, crutches or cane

          -  were willing to discontinue all nonsteroidal anti-inflammatory drugs (NSAIDs) or other
             analgesic medication (except for rescue medication) for the duration of the study

          -  did not receive physical therapy or trial of shoe modifications or orthotics during
             the study period

        Exclusion Criteria:

          -  pregnant and lactating women

          -  bilateral ankle OA requiring treatment of both ankles

          -  chronic ankle instability

          -  lower leg trauma other than within the ankle

          -  previous orthopedic surgery on the spine, hip or knee

          -  presence of active joint infections of foot or ankle

          -  previous surgery or arthroscopy on the ankle within 12 months

          -  intraarticular steroid or HA injection in the treated ankle within the past 6 months

          -  treatment with anticoagulants or immunosuppressives

          -  history of rheumatoid arthritis, gout, or any other inflammatory arthropathy

          -  history of avian protein allergy

          -  presence of other comorbidity (neoplasm, diabetes mellitus, paresis, recent trauma,
             etc) or poor health status that would interfere with the clinical assessments during
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shu-Fen Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans General Hospital, Kaohsiung, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Physical Medicine and Rehabilitation, Veterans General Hospital, Kaohsiung, Taiwan</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Salk RS, Chang TJ, D'Costa WF, Soomekh DJ, Grogan KA. Sodium hyaluronate in the treatment of osteoarthritis of the ankle: a controlled, randomized, double-blind pilot study. J Bone Joint Surg Am. 2006 Feb;88(2):295-302.</citation>
    <PMID>16452740</PMID>
  </reference>
  <reference>
    <citation>Sun SF, Chou YJ, Hsu CW, Hwang CW, Hsu PT, Wang JL, Hsu YW, Chou MC. Efficacy of intra-articular hyaluronic acid in patients with osteoarthritis of the ankle: a prospective study. Osteoarthritis Cartilage. 2006 Sep;14(9):867-74. Epub 2006 Apr 24.</citation>
    <PMID>16635582</PMID>
  </reference>
  <reference>
    <citation>Cohen MM, Altman RD, Hollstrom R, Hollstrom C, Sun C, Gipson B. Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. Foot Ankle Int. 2008 Jul;29(7):657-63.</citation>
    <PMID>18785414</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <results_first_submitted>March 16, 2009</results_first_submitted>
  <results_first_submitted_qc>April 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2009</results_first_posted>
  <last_update_submitted>June 11, 2009</last_update_submitted>
  <last_update_submitted_qc>June 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Shu-Fen Sun</name_title>
    <organization>Kaohsiung Veteran General Hospital</organization>
  </responsible_party>
  <keyword>Ankle joint</keyword>
  <keyword>Balance</keyword>
  <keyword>Hyaluronic acid</keyword>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fifty patients fulfilled the inclusion criteria and consented to take part in this study.</recruitment_details>
      <pre_assignment_details>One patient withdrew his consent and one had a fear of injection prior to receiving the first injection. Two patients withdrew from the study before the third injection (one because of an unrelated intercurrent illness and one moving to another city).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Hyaluronate Injection</title>
          <description>All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50">October, 2007</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46">October, 2008</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hyaluronate Injection</title>
          <description>All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Ankle Osteoarthritis Scale (AOS) Score at 6 Months</title>
        <description>The AOS is a patient-rated, validated outcome measure that includes nine items on a pain subscale and nine items on a disability subscale. Using the AOS, a score of 0 represent no pain or disability and 10 represent worst pain or disability imaginable</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>The statistical analysis was done on completers.</population>
        <group_list>
          <group group_id="O1">
            <title>Hyaluronate Injection</title>
            <description>All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Ankle Osteoarthritis Scale (AOS) Score at 6 Months</title>
          <description>The AOS is a patient-rated, validated outcome measure that includes nine items on a pain subscale and nine items on a disability subscale. Using the AOS, a score of 0 represent no pain or disability and 10 represent worst pain or disability imaginable</description>
          <population>The statistical analysis was done on completers.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Previous report using 5 weekly injections, mean AOS score reduction is 2.6 with the SD of 1.8 in 75 patients. To test whether AOS reduction would be &gt; 1 using pair t-test after 3 weekly injections, investigators need &gt; 42 patients to give &gt; 90% power to reject the null hypothesis-mean AOS score reduction &lt;1 at 6 months, given that both the mean and standard deviation of AOS score reduction equal to 2. Considering possible dropout of participants, investigators decide to include 50 patients</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The American Orthopedic Foot and Ankle Society (AOFAS) Ankle/Hindfoot Score</title>
        <description>The American Orthopedic Foot and Ankle Society (AOFAS) ankle/hindfoot score is a 100-point scale that devotes 40 points to pain, 50 points to function and 10 points to alignment. The maximum score of 100 points denotes no pain and normal function and alignment</description>
        <time_frame>6 months</time_frame>
        <posting_date>10/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ankle Sagittal Range of Motion</title>
        <description>Ankle sagittal ROM is the sum of ankle dorsiflexion and plantar flexion angles.</description>
        <time_frame>6 months</time_frame>
        <posting_date>09/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Four Clinical Balance Tests</title>
        <description>Single-leg stance test (SLS),The Functional Reach Test (FRT),Timed “ Up-and-Go” test (TUG) ,Berg Balance Scale (BBS)</description>
        <time_frame>6 months</time_frame>
        <posting_date>09/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Level of Global Satisfaction Based on a 7-point Categorical Scale</title>
        <description>The rating was based on a 7-point categorical scale weighted from completely satisfied, satisfied, somewhat satisfied, no change, somewhat unsatisfied, unsatisfied to completely unsatisfied.</description>
        <time_frame>6 months</time_frame>
        <posting_date>10/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic and Local Adverse Events Recording</title>
        <description>he occurrence of systemic and local adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded on a diary card</description>
        <time_frame>6 months</time_frame>
        <posting_date>10/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Acetaminophen Consumption</title>
        <description>The use of all analgesic medication during the study period was recorded on a diary card by the patient.</description>
        <time_frame>6 months</time_frame>
        <posting_date>10/2009</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hyaluronate Injection</title>
          <description>All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>8.7</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>brief post injection pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>local pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One limitation includes the absence of a control group, thus the placebo effects associated with joint injections were not investigated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shu-Fen Sun</name_or_title>
      <organization>Veterans General Hospital, Kaohsiung, Taiwan</organization>
      <phone>886-73422121 ext 4210</phone>
      <email>sfsun.tw@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

